Dr. Claire Harrison on the Benefits of Ruxolitinib in Advanced Myelofibrosis
Claire Harrison, MD, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.
Claire Harrison, MD, professor of hematology, Guy’s and St. Thomas’ NHS Foundation Trust, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.
Ruxolitinib was approved by the FDA in 2011 and improved and maintained reduction and overall survival in the the COMFORT-II study. In earlier findings that led to the therapy’s approval, published in 2012, ruxolitinib significantly decreased spleen size in 28% of patients, but no decrease was seen in patients in the control arm, who were taking best available therapy (BAT).
Harrison says the drug has significantly improved patients' lives and adds that there will be a study of ruxolitinib and its effects on early plhase myelofibrosis in the future.
MRD Negativity Improves With D-VRd in Newly Diagnosed, Transplant-Eligible Myeloma
September 6th 2024Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.
Read More
Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma
August 30th 2024During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
